Aurobindo Pharma’s wholly owned step-down subsidiary--CuraTeQ Biologics s.r.o. has obtained marketing authorisation from UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Zefylti, its filgrastim biosimilar version.
Earlier in February 2025, Zefylti had received the marketing authorisation in the European Union from the European Commission (EC). This is CuraTeQ’s second biosimilar to be approved by MHRA after the approval of Bevqolva in December 2024.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
